Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
China's National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one weight-related complication.Danish pharmaceutical company Novo Nordisk A/S (NYSE:NVO) said it will officially launch its weight-loss drug Wegovy in China.
丹麥藥品公司諾和諾德（紐交所代碼：NVO）表示，將在中國正式推出其減肥藥Wegovy。
China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
中國國家衛生健康委員會的調查顯示，超過一半的14億人口超重或肥胖。
Wegovy is the world's first weekly glucagon-like peptide-1 receptor agonist for long-term weight management.
Wegovy是全球首個用於長期體重管理的每週注射的類胰高血糖素肽-1受體激動劑。
China's National Medical Products Administration (NMPA) approved Wegovy in late June. It is intended for individuals with a body mass index (BMI) of 30 or higher who also have at least one weight-related complication.
中國國家藥品監督管理局（NMPA）在6月底批准了Wegovy。它適用於體重指數（BMI）爲30或以上並且至少有一種與體重相關的併發症的個體。
Also Read: Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
另請閱讀：Ozempic/Wegovy的maker在需求旺盛的情況下維持第三季度銷售增長
Initial sales of Wegovy in China will begin at a public hospital in Shanghai, where the first prescriptions are set to be issued this week, the financial media company Yicai noted.
Wegovy在中國的初始銷售將從上海的一家公立醫院開始，首批處方預計本週將發放，金融媒體公司第一財經報道。
The cost of a four-injection pack is reported to be around $194 (CNY 1,400) compared to around $1,349 per patient per month in the U.S.
一個四針裝的費用報告爲約194美元（人民幣1400元），而在美國，每位患者每月的費用約爲1349美元。
A month's prescription for Wegovy costs $186 in Denmark, $140 in Germany, and $92 in the U.K.
在丹麥，Wegovy一個月的處方費用爲186美元，在德國爲140美元，在英國爲92美元。
In the U.S., Novo Nordisk has been criticized for charging high prices for Wegovy and Ozempic.
在美國，諾和諾德因對Wegovy和Ozempic的高定價而受到批評。
While Novo Nordisk's CEO Lars Fruergaard Jørgensen has defended the high U.S. prices of the company's blockbuster drugs, Ozempic and Wegovy, stating that these medications are reducing the economic burden of obesity-related health issues.
雖然諾和諾德的首席執行官拉爾斯·弗魯爾加德·約根森爲公司暢銷藥Ozempic和Wegovy的高價格辯護，稱這些藥物減輕了與肥胖相關的健康問題所帶來的經濟負擔。
Due to the tight supply, access to the medication will be somewhat limited initially, requiring patients to schedule outpatient appointments and undergo a medication assessment.
由於供應緊張，初期藥物的獲取將受到一定限制，患者需預約門診並進行藥物評估。
Currently, Wegovy is not included in China's national medical insurance program.
目前，Wegovy尚未納入中國的國家醫療保險計劃。
Zhou Xiaping, Novo Nordisk's global senior vice president and president for China, noted that the company is actively pursuing strategies to make the drug more affordable, including potential partnerships with commercial insurance providers.
諾和諾德的全球高級副總裁兼中國區總裁周曉平指出，公司正在積極尋求策略，以使該藥物更加負擔得起，包括與商業保險提供商的潛在合作。
The Bloomberg report adds that while many patients in the U.S. and Europe get some help with drug costs through insurance, most Chinese consumers will need to pay for the drug themselves.
彭博社的報告補充稱，儘管許多美國和歐洲的患者通過保險獲得藥物費用的幫助，但大多數中國消費者需要自行支付藥物費用。
Price Action: NVO stock is down 1.67% at $100.04 at the last check on Monday.
價格走勢：NVO股票在週一最後一次檢查時下跌1.67%，報100.04美元。
- Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
- 禮來公司的Zepbound/Mounjaro在與肥胖相關的心力衰竭患者中顯示出心血管益處
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供
譯文內容由第三人軟體翻譯。
